Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
المؤلفون المشاركون
Fontana, Joseph A.
Vaishampayan, Ulka
Smith, Daryn
Freeman, Stacy
Heilbrun, Lance K.
Heath, Elisabeth I.
Baranowski, Karen
Ogita, Shin
Tejwani, Sheela
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-06-13
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Introduction/Background.
Nonmetastatic castrate resistant prostate cancer (CRPC) is a challenging disease state.
The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients.
Patients.
Patients with prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases and PSA progression despite androgen deprivation therapy.
Methods.
Bevacizumab 10 mg/kg intravenously was administered every 14 days until PSA progression, development of metastasis, or unacceptable toxicity.
Results.
15 patients were enrolled and treated with bevacizumab for a median duration of 3.1 months.
Median baseline PSA was 27 ng/mL, and seven patients had Gleason Score ≥8.
Five patients had declined in PSA during the treatment.
Median PSA doubling time was prolonged from 4.7 months pretreatment to 6.5 months.
Median time to PSA progression and new metastasis were 2.8 and 7.9 months, respectively.
There were three grade 3 adverse events (one proteinuria and two hypertension) and one pulmonary embolism.
There was no treatment-related mortality.
Conclusion.
Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC, and investigation of novel strategies is needed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ogita, Shin& Tejwani, Sheela& Heilbrun, Lance K.& Fontana, Joseph A.& Heath, Elisabeth I.& Freeman, Stacy…[et al.]. 2012. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology،Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-456746
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ogita, Shin…[et al.]. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology No. 2012 (2012), pp.1-7.
https://search.emarefa.net/detail/BIM-456746
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ogita, Shin& Tejwani, Sheela& Heilbrun, Lance K.& Fontana, Joseph A.& Heath, Elisabeth I.& Freeman, Stacy…[et al.]. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-456746
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-456746
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر